Cationic Lipid Nanoparticles for Lung Gene Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering gene therapy to the lungs face significant challenges, including the fragility of nucleic acid molecules and barriers such as mucus and pulmonary surfactant, which hinder efficient penetration and persistence of therapeutic agents, leading to low efficacy in treating conditions like cystic fibrosis.
Innovation Solution
The use of cationic lipid nanoparticles (LNPs) to deliver mRNAs or DNAs encoding engineered transcription factors or nucleases, which can target and integrate specific genes, such as the CFTR gene, to correct mutations like the Δ508 mutation, facilitating targeted gene editing and expression in lung cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional delivery methods are used for gene therapy to the lungs, then the delivery process is simple, but the penetration efficiency through mucus and surfactant barriers is poor
Solution Approach 1:
The patent employs lipid nanoparticles as intermediary carriers to deliver nucleic acid therapeutics to lung cells. These LNPs facilitate penetration through mucus and surfactant barriers, enabling efficient gene therapy delivery while maintaining manageable system complexity through standardized nanoparticle formulation.
2Reliability
If nucleic acid molecules are used for gene therapy, then the therapeutic potential is high, but the molecules are fragile and prone to degradation
Solution Approach 1:
The patent utilizes lipid nanoparticle shells to encapsulate and protect fragile nucleic acid molecules. This protective carrier system maintains nucleic acid integrity during delivery while preserving their therapeutic efficacy, resolving the contradiction between stability and productivity.
3Measurement precision
If targeted gene editing is achieved, then the treatment specificity is high, but the delivery efficiency to lung tissue is low
Solution Approach 1:
The patent optimizes parameters of the lipid nanoparticle formulation, including lipid composition, particle size, and surface charge, to enhance delivery efficiency to lung tissue. These parameter adjustments maintain the high specificity of targeted gene editing while significantly improving delivery productivity.
4Object-affected harmful factors
If mucus and surfactant barriers are present in the lungs, then the natural protective function is maintained, but the penetration of therapeutic agents is hindered
Solution Approach 1:
Lipid nanoparticles serve as intermediary carriers that interact with mucus and surfactant barriers, facilitating the penetration of nucleic acid therapeutics to lung cells while preserving the protective function of these natural barriers.
Data Source
AI summary
Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.